Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Asthma | 42 | 2022 | 955 | 3.570 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 13 | 2017 | 247 | 1.230 |
Why?
|
Cystic Fibrosis | 5 | 2022 | 112 | 1.160 |
Why?
|
Adrenal Cortex Hormones | 5 | 2021 | 263 | 0.790 |
Why?
|
Adrenergic beta-Agonists | 4 | 2013 | 72 | 0.670 |
Why?
|
Anti-Asthmatic Agents | 4 | 2014 | 76 | 0.660 |
Why?
|
Bronchoalveolar Lavage Fluid | 6 | 2017 | 121 | 0.660 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2018 | 57 | 0.650 |
Why?
|
Aminophenols | 1 | 2018 | 4 | 0.650 |
Why?
|
Benzodioxoles | 1 | 2018 | 16 | 0.640 |
Why?
|
Aminopyridines | 1 | 2018 | 38 | 0.630 |
Why?
|
Quinolones | 1 | 2018 | 60 | 0.620 |
Why?
|
Bronchodilator Agents | 5 | 2021 | 65 | 0.560 |
Why?
|
Bronchi | 8 | 2015 | 229 | 0.530 |
Why?
|
Glucocorticoids | 4 | 2019 | 352 | 0.500 |
Why?
|
Patient Education as Topic | 5 | 2016 | 351 | 0.410 |
Why?
|
Hospitalization | 7 | 2012 | 849 | 0.400 |
Why?
|
Adult | 51 | 2022 | 25648 | 0.400 |
Why?
|
Health Care Coalitions | 1 | 2011 | 9 | 0.400 |
Why?
|
Patient Selection | 3 | 2021 | 685 | 0.400 |
Why?
|
Community Health Planning | 1 | 2011 | 21 | 0.390 |
Why?
|
Administration, Inhalation | 10 | 2021 | 188 | 0.390 |
Why?
|
Salmeterol Xinafoate | 2 | 2021 | 16 | 0.390 |
Why?
|
Fluticasone | 2 | 2021 | 30 | 0.390 |
Why?
|
Humidity | 10 | 2008 | 89 | 0.380 |
Why?
|
Muscle, Smooth | 6 | 2015 | 354 | 0.380 |
Why?
|
Forced Expiratory Volume | 8 | 2018 | 122 | 0.370 |
Why?
|
Male | 57 | 2021 | 40965 | 0.360 |
Why?
|
Mitogens | 3 | 1999 | 64 | 0.350 |
Why?
|
Lung | 10 | 2017 | 1170 | 0.340 |
Why?
|
Chromosomes, Human, Pair 17 | 2 | 2020 | 110 | 0.340 |
Why?
|
Humans | 74 | 2022 | 86643 | 0.340 |
Why?
|
Female | 54 | 2022 | 44532 | 0.330 |
Why?
|
Small-Area Analysis | 1 | 2007 | 8 | 0.320 |
Why?
|
DNA Methylation | 4 | 2022 | 628 | 0.320 |
Why?
|
Microbiota | 3 | 2019 | 381 | 0.320 |
Why?
|
Respiratory System | 2 | 2019 | 116 | 0.310 |
Why?
|
Hyperoxia | 3 | 1995 | 34 | 0.290 |
Why?
|
Anti-Inflammatory Agents | 4 | 2015 | 339 | 0.290 |
Why?
|
Metered Dose Inhalers | 3 | 2016 | 33 | 0.280 |
Why?
|
Nasal Mucosa | 8 | 2004 | 186 | 0.280 |
Why?
|
Epigenesis, Genetic | 3 | 2022 | 479 | 0.270 |
Why?
|
Middle Aged | 33 | 2021 | 25028 | 0.270 |
Why?
|
Urban Health | 2 | 2011 | 55 | 0.270 |
Why?
|
Chicago | 8 | 2019 | 1379 | 0.270 |
Why?
|
Health Status Disparities | 1 | 2007 | 170 | 0.270 |
Why?
|
Hot Temperature | 7 | 2008 | 206 | 0.260 |
Why?
|
HLA-G Antigens | 2 | 2017 | 52 | 0.260 |
Why?
|
Air | 6 | 2008 | 62 | 0.250 |
Why?
|
Eosinophils | 3 | 2019 | 194 | 0.240 |
Why?
|
Smoking | 3 | 2017 | 609 | 0.240 |
Why?
|
Nebulizers and Vaporizers | 2 | 2016 | 55 | 0.230 |
Why?
|
Catheter Ablation | 3 | 2015 | 233 | 0.230 |
Why?
|
Child | 12 | 2022 | 6927 | 0.230 |
Why?
|
Nose | 4 | 2008 | 94 | 0.230 |
Why?
|
Genetic Predisposition to Disease | 4 | 2021 | 2271 | 0.230 |
Why?
|
Hypersensitivity, Immediate | 3 | 2019 | 62 | 0.230 |
Why?
|
Bronchiectasis | 2 | 2013 | 13 | 0.230 |
Why?
|
Biomedical Research | 2 | 2019 | 376 | 0.220 |
Why?
|
MicroRNAs | 2 | 2021 | 534 | 0.220 |
Why?
|
Gene Expression Profiling | 2 | 2020 | 1384 | 0.220 |
Why?
|
Nasal Cavity | 5 | 2004 | 91 | 0.220 |
Why?
|
Interleukin-33 | 1 | 2021 | 24 | 0.210 |
Why?
|
Neutrophils | 4 | 2019 | 307 | 0.210 |
Why?
|
Otolaryngology | 1 | 2022 | 53 | 0.200 |
Why?
|
Pharmacogenomic Testing | 1 | 2021 | 97 | 0.190 |
Why?
|
Reproducibility of Results | 5 | 2021 | 2705 | 0.190 |
Why?
|
Social Class | 1 | 2021 | 128 | 0.190 |
Why?
|
Adolescent | 12 | 2021 | 8981 | 0.190 |
Why?
|
Epithelial Cells | 4 | 2021 | 669 | 0.190 |
Why?
|
Spirometry | 3 | 2017 | 66 | 0.190 |
Why?
|
Health Planning | 1 | 1999 | 17 | 0.180 |
Why?
|
Minority Groups | 1 | 2021 | 137 | 0.180 |
Why?
|
Cross-Sectional Studies | 8 | 2017 | 1621 | 0.180 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 23 | 0.180 |
Why?
|
Electronic Prescribing | 1 | 2019 | 11 | 0.180 |
Why?
|
Sinusitis | 1 | 2022 | 210 | 0.180 |
Why?
|
Enhancer Elements, Genetic | 1 | 2021 | 266 | 0.180 |
Why?
|
Fungi | 1 | 2019 | 65 | 0.170 |
Why?
|
Bronchoscopy | 4 | 2015 | 152 | 0.160 |
Why?
|
Epistasis, Genetic | 1 | 2019 | 86 | 0.160 |
Why?
|
Child, Preschool | 7 | 2019 | 3612 | 0.160 |
Why?
|
Genetic Association Studies | 1 | 2020 | 294 | 0.160 |
Why?
|
Th2 Cells | 1 | 2019 | 146 | 0.160 |
Why?
|
Neoplasm Proteins | 2 | 2020 | 532 | 0.160 |
Why?
|
Gene Expression Regulation | 3 | 2022 | 1920 | 0.160 |
Why?
|
Interleukin-6 | 1 | 2019 | 256 | 0.160 |
Why?
|
Aged | 17 | 2019 | 18415 | 0.160 |
Why?
|
Patient Outcome Assessment | 1 | 2017 | 84 | 0.150 |
Why?
|
Gene Expression | 2 | 2018 | 1284 | 0.150 |
Why?
|
Sputum | 2 | 2017 | 34 | 0.150 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 865 | 0.150 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 243 | 0.140 |
Why?
|
Respiratory System Agents | 1 | 2016 | 7 | 0.140 |
Why?
|
Self Care | 3 | 2016 | 164 | 0.140 |
Why?
|
Sleep Wake Disorders | 1 | 2017 | 115 | 0.140 |
Why?
|
Bacteria | 2 | 2017 | 447 | 0.140 |
Why?
|
Smokers | 1 | 2016 | 41 | 0.140 |
Why?
|
Intention | 1 | 2016 | 51 | 0.140 |
Why?
|
Community Health Workers | 2 | 2006 | 26 | 0.140 |
Why?
|
Cross-Over Studies | 8 | 2019 | 399 | 0.140 |
Why?
|
Patient Compliance | 1 | 2016 | 227 | 0.130 |
Why?
|
CpG Islands | 3 | 2022 | 151 | 0.130 |
Why?
|
Genome-Wide Association Study | 2 | 2022 | 1621 | 0.130 |
Why?
|
International Classification of Diseases | 2 | 2014 | 69 | 0.130 |
Why?
|
Prednisone | 1 | 2015 | 258 | 0.130 |
Why?
|
Membrane Proteins | 2 | 2020 | 1196 | 0.130 |
Why?
|
Pentoxifylline | 1 | 1994 | 9 | 0.130 |
Why?
|
Delivery of Health Care | 1 | 1999 | 426 | 0.130 |
Why?
|
Pregnenediones | 1 | 2014 | 8 | 0.120 |
Why?
|
Practice Guidelines as Topic | 3 | 2014 | 1036 | 0.120 |
Why?
|
Air Pressure | 1 | 1994 | 7 | 0.120 |
Why?
|
Body Temperature | 3 | 2005 | 124 | 0.120 |
Why?
|
Sarcoidosis, Pulmonary | 1 | 2014 | 17 | 0.120 |
Why?
|
Young Adult | 7 | 2021 | 5976 | 0.120 |
Why?
|
Cholecalciferol | 1 | 2014 | 35 | 0.120 |
Why?
|
Electronic Health Records | 1 | 2017 | 319 | 0.120 |
Why?
|
Pseudomonas Infections | 1 | 2014 | 95 | 0.120 |
Why?
|
Quality of Life | 3 | 2022 | 1585 | 0.120 |
Why?
|
Smoking Cessation | 1 | 2016 | 230 | 0.120 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2021 | 2357 | 0.120 |
Why?
|
Adalimumab | 1 | 2014 | 80 | 0.120 |
Why?
|
United States | 9 | 2021 | 6672 | 0.120 |
Why?
|
Vitamins | 1 | 2014 | 81 | 0.120 |
Why?
|
Phenotype | 4 | 2022 | 2378 | 0.110 |
Why?
|
Respiratory Mechanics | 1 | 1994 | 102 | 0.110 |
Why?
|
Activities of Daily Living | 1 | 2014 | 204 | 0.110 |
Why?
|
Vitamin D Deficiency | 1 | 2014 | 103 | 0.110 |
Why?
|
Health Education | 2 | 2006 | 101 | 0.110 |
Why?
|
Patient Care Management | 1 | 2012 | 31 | 0.110 |
Why?
|
RNA, Ribosomal, 16S | 3 | 2019 | 241 | 0.110 |
Why?
|
Anti-Bacterial Agents | 2 | 2014 | 746 | 0.110 |
Why?
|
Anti-Infective Agents | 1 | 2013 | 89 | 0.110 |
Why?
|
Comparative Effectiveness Research | 1 | 2012 | 53 | 0.110 |
Why?
|
Nasal Provocation Tests | 3 | 2001 | 129 | 0.110 |
Why?
|
Trachea | 3 | 1999 | 293 | 0.100 |
Why?
|
Chest Wall Oscillation | 1 | 2011 | 5 | 0.100 |
Why?
|
Skin Temperature | 2 | 2003 | 14 | 0.100 |
Why?
|
Obesity | 1 | 2018 | 963 | 0.100 |
Why?
|
Clinical Coding | 1 | 2011 | 23 | 0.100 |
Why?
|
Community Pharmacy Services | 1 | 2011 | 5 | 0.100 |
Why?
|
Drug Utilization Review | 1 | 2011 | 14 | 0.100 |
Why?
|
Academic Medical Centers | 2 | 2011 | 379 | 0.100 |
Why?
|
Societies, Medical | 1 | 2014 | 572 | 0.100 |
Why?
|
Cytokines | 3 | 2021 | 776 | 0.100 |
Why?
|
Rats, Sprague-Dawley | 6 | 1995 | 1219 | 0.090 |
Why?
|
Equipment Failure | 1 | 2011 | 119 | 0.090 |
Why?
|
Postoperative Complications | 2 | 2015 | 2207 | 0.090 |
Why?
|
Quantitative Trait Loci | 3 | 2020 | 576 | 0.090 |
Why?
|
Air Pollution, Indoor | 1 | 2011 | 63 | 0.090 |
Why?
|
Patient Participation | 1 | 2012 | 216 | 0.090 |
Why?
|
Inflammation | 1 | 2015 | 920 | 0.090 |
Why?
|
Rhinitis, Allergic, Seasonal | 5 | 2001 | 179 | 0.090 |
Why?
|
Inpatients | 1 | 2012 | 297 | 0.090 |
Why?
|
Health Services Research | 1 | 2010 | 136 | 0.090 |
Why?
|
Prevalence | 3 | 2011 | 1239 | 0.090 |
Why?
|
Cell Division | 4 | 1999 | 696 | 0.080 |
Why?
|
Acute Disease | 4 | 2012 | 826 | 0.080 |
Why?
|
Prospective Studies | 6 | 2019 | 4213 | 0.080 |
Why?
|
Phenoxybenzamine | 2 | 2005 | 15 | 0.080 |
Why?
|
Genotype | 3 | 2020 | 1851 | 0.080 |
Why?
|
Airway Obstruction | 1 | 2009 | 109 | 0.080 |
Why?
|
Adrenergic alpha-Antagonists | 2 | 2005 | 35 | 0.080 |
Why?
|
Foot | 3 | 2003 | 50 | 0.080 |
Why?
|
Perception | 1 | 2009 | 168 | 0.080 |
Why?
|
Aged, 80 and over | 4 | 2017 | 6509 | 0.080 |
Why?
|
Risk Factors | 3 | 2022 | 5417 | 0.080 |
Why?
|
Continuous Positive Airway Pressure | 1 | 2008 | 53 | 0.080 |
Why?
|
Cohort Studies | 4 | 2018 | 2767 | 0.080 |
Why?
|
Linear Models | 3 | 2017 | 421 | 0.070 |
Why?
|
Double-Blind Method | 4 | 2019 | 1823 | 0.070 |
Why?
|
Vital Capacity | 2 | 2017 | 64 | 0.070 |
Why?
|
Rats | 6 | 1995 | 3990 | 0.070 |
Why?
|
Disease Progression | 1 | 2011 | 1531 | 0.070 |
Why?
|
Mutation | 1 | 2018 | 3968 | 0.070 |
Why?
|
Risk-Taking | 1 | 2007 | 148 | 0.070 |
Why?
|
Population Surveillance | 1 | 2007 | 219 | 0.070 |
Why?
|
Water | 2 | 2005 | 277 | 0.070 |
Why?
|
Algorithms | 2 | 2011 | 1830 | 0.070 |
Why?
|
Incidence | 3 | 2012 | 1577 | 0.070 |
Why?
|
Cells, Cultured | 4 | 1999 | 2818 | 0.070 |
Why?
|
Olfactory Mucosa | 1 | 2005 | 33 | 0.060 |
Why?
|
Health Status Indicators | 1 | 2005 | 105 | 0.060 |
Why?
|
Medicaid | 1 | 2007 | 217 | 0.060 |
Why?
|
Ipratropium | 2 | 2003 | 18 | 0.060 |
Why?
|
Research | 1 | 2005 | 253 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2019 | 1961 | 0.060 |
Why?
|
Multivariate Analysis | 2 | 2017 | 999 | 0.060 |
Why?
|
Databases as Topic | 1 | 2004 | 92 | 0.060 |
Why?
|
Severity of Illness Index | 3 | 2016 | 1801 | 0.060 |
Why?
|
Budesonide | 1 | 2004 | 45 | 0.060 |
Why?
|
Drug Prescriptions | 1 | 2005 | 141 | 0.060 |
Why?
|
Rhinitis, Allergic, Perennial | 2 | 2001 | 81 | 0.060 |
Why?
|
Environmental Exposure | 1 | 2006 | 296 | 0.060 |
Why?
|
Cell Movement | 2 | 1999 | 758 | 0.060 |
Why?
|
Protein C | 1 | 2003 | 5 | 0.060 |
Why?
|
Logistic Models | 2 | 2017 | 1186 | 0.060 |
Why?
|
Mothers | 2 | 2022 | 141 | 0.060 |
Why?
|
Recurrence | 3 | 2011 | 1139 | 0.060 |
Why?
|
Reflex | 1 | 2003 | 79 | 0.060 |
Why?
|
Treatment Failure | 2 | 2014 | 285 | 0.060 |
Why?
|
Temperature | 2 | 2001 | 396 | 0.060 |
Why?
|
In Vitro Techniques | 2 | 1995 | 989 | 0.060 |
Why?
|
Cell Count | 2 | 1999 | 195 | 0.050 |
Why?
|
Adult Children | 1 | 2022 | 12 | 0.050 |
Why?
|
Emergency Medical Services | 1 | 2005 | 209 | 0.050 |
Why?
|
Patient Acuity | 1 | 2022 | 32 | 0.050 |
Why?
|
Bronchial Provocation Tests | 2 | 1999 | 24 | 0.050 |
Why?
|
Transcriptome | 2 | 2017 | 580 | 0.050 |
Why?
|
Japan | 1 | 2022 | 307 | 0.050 |
Why?
|
Practice Patterns, Physicians' | 1 | 2007 | 582 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2005 | 394 | 0.050 |
Why?
|
Asthma, Exercise-Induced | 1 | 2001 | 6 | 0.050 |
Why?
|
Allergens | 2 | 2000 | 179 | 0.050 |
Why?
|
Octamer Transcription Factor-1 | 1 | 2021 | 17 | 0.050 |
Why?
|
Supine Position | 1 | 2001 | 30 | 0.050 |
Why?
|
Ceftizoxime | 1 | 2001 | 3 | 0.050 |
Why?
|
Platelet-Derived Growth Factor | 3 | 1999 | 67 | 0.050 |
Why?
|
Suppressor of Cytokine Signaling Proteins | 1 | 2021 | 20 | 0.050 |
Why?
|
Histamine | 1 | 2001 | 126 | 0.050 |
Why?
|
Ribonucleases | 1 | 2001 | 92 | 0.050 |
Why?
|
Hemolysis | 1 | 2001 | 61 | 0.050 |
Why?
|
Oxygen | 3 | 1995 | 726 | 0.050 |
Why?
|
Recombinant Proteins | 1 | 2003 | 1014 | 0.050 |
Why?
|
Intensive Care Units | 1 | 2004 | 373 | 0.050 |
Why?
|
Infant | 3 | 2019 | 3046 | 0.050 |
Why?
|
Animals | 9 | 2021 | 26582 | 0.050 |
Why?
|
Body Temperature Regulation | 1 | 2000 | 56 | 0.050 |
Why?
|
Antigens | 1 | 2001 | 228 | 0.050 |
Why?
|
Reaction Time | 1 | 2001 | 309 | 0.050 |
Why?
|
Consensus | 1 | 2022 | 335 | 0.050 |
Why?
|
Geography | 1 | 2021 | 223 | 0.050 |
Why?
|
Phosphorylation | 2 | 1999 | 1106 | 0.050 |
Why?
|
Case-Control Studies | 3 | 2016 | 1805 | 0.050 |
Why?
|
Consumer Health Informatics | 1 | 2019 | 3 | 0.040 |
Why?
|
Cyclin D1 | 1 | 1999 | 83 | 0.040 |
Why?
|
Sepsis | 1 | 2003 | 306 | 0.040 |
Why?
|
Organ Transplantation | 1 | 2003 | 265 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 894 | 0.040 |
Why?
|
Leukocytes, Mononuclear | 1 | 2020 | 196 | 0.040 |
Why?
|
Molecular Weight | 2 | 1999 | 332 | 0.040 |
Why?
|
Administration, Intranasal | 3 | 2005 | 136 | 0.040 |
Why?
|
Drug Combinations | 1 | 2019 | 224 | 0.040 |
Why?
|
Zebrafish | 1 | 2021 | 309 | 0.040 |
Why?
|
Focus Groups | 1 | 2019 | 155 | 0.040 |
Why?
|
Comorbidity | 1 | 2022 | 943 | 0.040 |
Why?
|
Chromatin | 1 | 2021 | 380 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 1999 | 222 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 1999 | 101 | 0.040 |
Why?
|
Linkage Disequilibrium | 1 | 2020 | 473 | 0.040 |
Why?
|
Forecasting | 1 | 1999 | 304 | 0.040 |
Why?
|
Promoter Regions, Genetic | 1 | 2021 | 937 | 0.040 |
Why?
|
Alleles | 1 | 2021 | 1128 | 0.040 |
Why?
|
Health Information Exchange | 1 | 2017 | 12 | 0.040 |
Why?
|
Mice, Transgenic | 1 | 2021 | 1540 | 0.040 |
Why?
|
Protein-Tyrosine Kinases | 1 | 1999 | 302 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2012 | 751 | 0.040 |
Why?
|
Metabolome | 1 | 2017 | 47 | 0.040 |
Why?
|
Metabolic Networks and Pathways | 1 | 2017 | 79 | 0.040 |
Why?
|
Self Administration | 1 | 2016 | 73 | 0.040 |
Why?
|
Immunoglobulin E | 1 | 2017 | 144 | 0.040 |
Why?
|
Respiratory Sounds | 1 | 2016 | 33 | 0.040 |
Why?
|
DNA, Bacterial | 1 | 2017 | 236 | 0.040 |
Why?
|
Cooperative Behavior | 1 | 2017 | 174 | 0.040 |
Why?
|
Cough | 1 | 2016 | 54 | 0.040 |
Why?
|
Educational Status | 1 | 2016 | 188 | 0.030 |
Why?
|
Equipment Failure Analysis | 1 | 2016 | 90 | 0.030 |
Why?
|
Dyspnea | 1 | 2016 | 73 | 0.030 |
Why?
|
Observer Variation | 1 | 2017 | 602 | 0.030 |
Why?
|
Infant, Newborn | 2 | 2019 | 2379 | 0.030 |
Why?
|
Checklist | 1 | 2016 | 57 | 0.030 |
Why?
|
Survival Analysis | 1 | 1999 | 1538 | 0.030 |
Why?
|
Hand Strength | 1 | 1995 | 51 | 0.030 |
Why?
|
Nitric Oxide | 1 | 2017 | 278 | 0.030 |
Why?
|
Health Literacy | 1 | 2016 | 70 | 0.030 |
Why?
|
RNA, Bacterial | 1 | 2015 | 108 | 0.030 |
Why?
|
Eosinophilia | 1 | 2015 | 84 | 0.030 |
Why?
|
Equipment Design | 1 | 2016 | 406 | 0.030 |
Why?
|
Firearms | 1 | 1995 | 48 | 0.030 |
Why?
|
Urban Population | 2 | 2006 | 213 | 0.030 |
Why?
|
Biopsy | 2 | 2015 | 1163 | 0.030 |
Why?
|
S Phase | 1 | 1994 | 62 | 0.030 |
Why?
|
Odds Ratio | 1 | 2016 | 678 | 0.030 |
Why?
|
Poverty | 2 | 2006 | 173 | 0.030 |
Why?
|
Tantalum | 1 | 1994 | 5 | 0.030 |
Why?
|
Surface Tension | 1 | 1994 | 8 | 0.030 |
Why?
|
1,2-Dipalmitoylphosphatidylcholine | 1 | 1994 | 9 | 0.030 |
Why?
|
Computer Simulation | 1 | 2019 | 1078 | 0.030 |
Why?
|
Bronchial Hyperreactivity | 1 | 1994 | 77 | 0.030 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2017 | 425 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 1995 | 154 | 0.030 |
Why?
|
Genome, Human | 1 | 2019 | 756 | 0.030 |
Why?
|
Child Development | 1 | 1995 | 163 | 0.030 |
Why?
|
Macrolides | 1 | 2013 | 31 | 0.030 |
Why?
|
Retrospective Studies | 3 | 2012 | 8489 | 0.030 |
Why?
|
Fatigue | 1 | 2014 | 174 | 0.030 |
Why?
|
Exercise Therapy | 1 | 2013 | 80 | 0.030 |
Why?
|
Lung Diseases, Obstructive | 1 | 2012 | 19 | 0.030 |
Why?
|
Mental Health | 1 | 2014 | 162 | 0.030 |
Why?
|
Analysis of Variance | 3 | 2001 | 912 | 0.030 |
Why?
|
Databases, Factual | 1 | 2016 | 814 | 0.030 |
Why?
|
Maternal Exposure | 1 | 2013 | 57 | 0.030 |
Why?
|
Pain Measurement | 1 | 2014 | 321 | 0.030 |
Why?
|
Airway Management | 1 | 2013 | 46 | 0.030 |
Why?
|
Aspergillosis, Allergic Bronchopulmonary | 1 | 2012 | 7 | 0.030 |
Why?
|
Psychometrics | 1 | 2014 | 327 | 0.030 |
Why?
|
Patient Advocacy | 1 | 2012 | 49 | 0.030 |
Why?
|
Time Factors | 3 | 2014 | 5210 | 0.030 |
Why?
|
Respiratory Mucosa | 1 | 2013 | 88 | 0.030 |
Why?
|
Administration, Oral | 1 | 2014 | 684 | 0.030 |
Why?
|
Immersion | 2 | 2003 | 21 | 0.030 |
Why?
|
Respiratory Function Tests | 1 | 2012 | 136 | 0.030 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2012 | 57 | 0.030 |
Why?
|
Radiography | 1 | 1994 | 813 | 0.030 |
Why?
|
Fibroblasts | 1 | 1995 | 729 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2016 | 508 | 0.030 |
Why?
|
Social Behavior | 1 | 2014 | 294 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 2 | 1994 | 1204 | 0.020 |
Why?
|
Arthritis, Rheumatoid | 1 | 2012 | 166 | 0.020 |
Why?
|
Pseudomonas aeruginosa | 1 | 2012 | 194 | 0.020 |
Why?
|
Biomarkers | 1 | 2017 | 1718 | 0.020 |
Why?
|
Patient-Centered Care | 1 | 2012 | 203 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2013 | 429 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2012 | 320 | 0.020 |
Why?
|
Autoimmune Diseases | 1 | 2012 | 241 | 0.020 |
Why?
|
Respiratory Care Units | 1 | 2009 | 4 | 0.020 |
Why?
|
Sleep | 1 | 2014 | 444 | 0.020 |
Why?
|
Data Collection | 1 | 2011 | 372 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2014 | 7993 | 0.020 |
Why?
|
Chronic Disease | 1 | 2012 | 971 | 0.020 |
Why?
|
Hematologic Neoplasms | 1 | 2012 | 329 | 0.020 |
Why?
|
Risk Assessment | 1 | 2016 | 2261 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2010 | 349 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2014 | 1376 | 0.020 |
Why?
|
Length of Stay | 1 | 2010 | 702 | 0.020 |
Why?
|
Models, Biological | 1 | 1994 | 1749 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2011 | 1673 | 0.020 |
Why?
|
Signal Transduction | 1 | 1997 | 3241 | 0.020 |
Why?
|
Patient Discharge | 1 | 2009 | 300 | 0.020 |
Why?
|
Housing | 1 | 2006 | 42 | 0.020 |
Why?
|
Surveys and Questionnaires | 1 | 2014 | 2501 | 0.020 |
Why?
|
Placebo Effect | 1 | 2005 | 31 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2012 | 3640 | 0.020 |
Why?
|
Specific Pathogen-Free Organisms | 2 | 1995 | 74 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2006 | 567 | 0.010 |
Why?
|
Cholinergic Antagonists | 1 | 2003 | 26 | 0.010 |
Why?
|
Epithelium | 2 | 1994 | 319 | 0.010 |
Why?
|
Lidocaine | 1 | 2003 | 63 | 0.010 |
Why?
|
Regional Blood Flow | 1 | 2003 | 197 | 0.010 |
Why?
|
Sympathetic Nervous System | 1 | 2003 | 104 | 0.010 |
Why?
|
Anesthetics, Local | 1 | 2003 | 76 | 0.010 |
Why?
|
Pancreas Transplantation | 1 | 2003 | 103 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2005 | 1019 | 0.010 |
Why?
|
Eosinophil Granule Proteins | 1 | 2001 | 20 | 0.010 |
Why?
|
Atmosphere Exposure Chambers | 1 | 2001 | 7 | 0.010 |
Why?
|
Nasal Lavage Fluid | 1 | 2001 | 26 | 0.010 |
Why?
|
Adsorption | 1 | 2001 | 54 | 0.010 |
Why?
|
Blood Proteins | 1 | 2001 | 144 | 0.010 |
Why?
|
Serum Albumin | 1 | 2001 | 130 | 0.010 |
Why?
|
Air Conditioning | 1 | 2001 | 6 | 0.010 |
Why?
|
Antigen-Antibody Complex | 1 | 2001 | 87 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2001 | 307 | 0.010 |
Why?
|
Acoustics | 1 | 2001 | 51 | 0.010 |
Why?
|
Leukocytes | 1 | 2001 | 202 | 0.010 |
Why?
|
Random Allocation | 1 | 2001 | 332 | 0.010 |
Why?
|
Isoantibodies | 1 | 2001 | 114 | 0.010 |
Why?
|
Skin Tests | 1 | 1999 | 44 | 0.010 |
Why?
|
Methacholine Chloride | 1 | 1999 | 64 | 0.010 |
Why?
|
Leukocyte Count | 1 | 1999 | 220 | 0.010 |
Why?
|
Pulmonary Alveoli | 1 | 1999 | 71 | 0.010 |
Why?
|
Chromatography, Gel | 1 | 1999 | 103 | 0.010 |
Why?
|
Nasopharynx | 1 | 1999 | 47 | 0.010 |
Why?
|
Colforsin | 1 | 1999 | 74 | 0.010 |
Why?
|
MAP Kinase Kinase 1 | 1 | 1999 | 36 | 0.010 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 1999 | 268 | 0.010 |
Why?
|
Respiration | 1 | 2000 | 262 | 0.010 |
Why?
|
DNA | 2 | 1995 | 1294 | 0.010 |
Why?
|
Cattle | 1 | 1999 | 376 | 0.010 |
Why?
|
Enzyme Activation | 1 | 1999 | 692 | 0.010 |
Why?
|
Blotting, Western | 1 | 1999 | 782 | 0.010 |
Why?
|
Bronchopulmonary Dysplasia | 1 | 1997 | 39 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 2003 | 849 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1995 | 274 | 0.010 |
Why?
|
Motor Skills | 1 | 1995 | 71 | 0.010 |
Why?
|
Blood | 1 | 1995 | 69 | 0.010 |
Why?
|
Liver Transplantation | 1 | 2003 | 1268 | 0.010 |
Why?
|
Bromodeoxyuridine | 1 | 1994 | 57 | 0.010 |
Why?
|
Culture Media, Conditioned | 1 | 1995 | 104 | 0.010 |
Why?
|
Hypertrophy | 1 | 1994 | 62 | 0.010 |
Why?
|
Airway Resistance | 1 | 1994 | 69 | 0.010 |
Why?
|
Aerosols | 1 | 1994 | 44 | 0.010 |
Why?
|
Insulin-Like Growth Factor I | 1 | 1995 | 114 | 0.010 |
Why?
|
Acetylcholine | 1 | 1994 | 176 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 1994 | 503 | 0.010 |
Why?
|
Sex Characteristics | 1 | 1995 | 319 | 0.010 |
Why?
|
Body Weight | 1 | 1994 | 459 | 0.010 |
Why?
|
Age Factors | 1 | 1994 | 1851 | 0.010 |
Why?
|
RNA, Messenger | 1 | 1995 | 1981 | 0.010 |
Why?
|